Kasuni Gayathri Ileperuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kasuni Gayathri Ileperuma has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Fozia Rustamani
Chulalongkorn University
1 shared publication - Nonthaneth Nalinratana
Center of Excellence in Natural Products for Ageing and Chronic Diseases, Chulalongkorn University, Bangkok 10330, Thailand
1 shared publication - Thawanrat Chirapiriyakul
Chulalongkorn University
1 shared publication
Latest Publications
- 15 August 2026
- Published by ACG Publications in Records of Natural Products
- Vol. 21 (1)
Pongamol from Millettia erythrocalyx preferentially inhibited MDA-MB-231 cells and induced G2/M arrest associated with CDK1 inhibition
Normal 0 false false false false EN-US X-NONE TH /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-ansi-language:EN;} Normal 0 false false false false EN-US X-NONE TH /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-ansi-language:EN;} Triple-negative breast cancer (TNBC) lacks targeted therapies, creating a need for selective antiproliferative agents. We evaluated pongamol, a flavonoid from the roots of Millettia erythrocalyx Gagnep., against MDA-MB-231 TNBC cells, using the non-tumorigenic line MCF-10A as a normal-cell control. Pongamol preferentially reduced MDA-MB-231 viability (54.95 ± 7.08% versus 83.10 ± 6.34% at 200 µM after 24 h). After 72 h the IC50 was 65.83 ± 4.65 µM in MDA-MB-231 cells but approximately 200 µM in MCF-10A cells, giving a selectivity index of about 3. Network pharmacology identified 83 shared targets, with CDK1 among the protein–protein interaction hubs and Gene Ontology enrichment dominated by regulation of the G2/M transition. Pongamol inhibited proliferation (to 47% at 50 µM) and colony formation (to 31% of control at 25 µM), and induced G2/M arrest at 5 µM with a progressive increase in the sub-G1 population. In a cell-free assay, pongamol inhibited CDK1/cyclin B1 kinase activity (IC50 = 22.15 ± 4.23 µM), and docking predicted that it occupies the CDK1 ATP-binding site. These findings identify pongamol as a preferentially active, CDK1-inhibiting lead compound in the MDA-MB-231 model of TNBC, warranting validation in additional TNBC cell lines.
- 15 August 2026
- Published by ACG Publications in Records of Natural Products
- Vol. 21 (1)
Pongamol from Millettia erythrocalyx preferentially inhibited MDA-MB-231 cells and induced G2/M arrest associated with CDK1 inhibition
Normal 0 false false false false EN-US X-NONE TH /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-ansi-language:EN;} Normal 0 false false false false EN-US X-NONE TH /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-ansi-language:EN;} Triple-negative breast cancer (TNBC) lacks targeted therapies, creating a need for selective antiproliferative agents. We evaluated pongamol, a flavonoid from the roots of Millettia erythrocalyx Gagnep., against MDA-MB-231 TNBC cells, using the non-tumorigenic line MCF-10A as a normal-cell control. Pongamol preferentially reduced MDA-MB-231 viability (54.95 ± 7.08% versus 83.10 ± 6.34% at 200 µM after 24 h). After 72 h the IC50 was 65.83 ± 4.65 µM in MDA-MB-231 cells but approximately 200 µM in MCF-10A cells, giving a selectivity index of about 3. Network pharmacology identified 83 shared targets, with CDK1 among the protein–protein interaction hubs and Gene Ontology enrichment dominated by regulation of the G2/M transition. Pongamol inhibited proliferation (to 47% at 50 µM) and colony formation (to 31% of control at 25 µM), and induced G2/M arrest at 5 µM with a progressive increase in the sub-G1 population. In a cell-free assay, pongamol inhibited CDK1/cyclin B1 kinase activity (IC50 = 22.15 ± 4.23 µM), and docking predicted that it occupies the CDK1 ATP-binding site. These findings identify pongamol as a preferentially active, CDK1-inhibiting lead compound in the MDA-MB-231 model of TNBC, warranting validation in additional TNBC cell lines.